Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Oncotarget - 22 Nov 2016

Raaijmakers Marieke I G, Widmer Daniel S, Narechania Apurva, Eichhoff Ossia, Freiberger Sandra N, Wenzina Judith, Cheng Phil F, Mihic-Probst Daniela, Desalle Rob, Dummer Reinhard, Levesque Mitchell P

Abstract excerpt

Acquired chemotherapeutic resistance of cancer cells can result from a Darwinistic evolution process in which heterogeneity plays an important role. In order to understand the impact of genetic heterogeneity on acquired resistance and second line therapy selection in metastatic melanoma, we sequenced the exomes of 27 lesions which were collected from 3 metastatic melanoma patients treated with targeted or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Single-Cell Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27791198
DOI: 10.18632/oncotarget.12848
PMCID: PMC5363577

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.PMID 27791198Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.Semantic proximity Read ↗

Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting OutcomesSemantic proximity Read ↗

The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.Semantic proximity Read ↗

Treatment Resistance to Melanoma Therapeutics on a Single Cell LevelSemantic proximity Read ↗

Treatment resistance to melanoma therapeutics on a single cell level.Semantic proximity Read ↗

Single-cell genomics analysis reveals complex genetic interactions in an in vivo model of acquired BRAF inhibitor resistance.Semantic proximity Read ↗

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.Semantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.Semantic proximity Read ↗

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.